Leung AWY - Search Results

1

Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.

Leung AWY, Anantha M, Dragowska WH, Wehbe M, Bally MB. Leung AWY, et al. J Control Release. 2018 Sep 28;286:1-9. doi: 10.1016/j.jconrel.2018.07.025. Epub 2018 Jul 18. J Control Release. 2018. PMID: 30016731 Free article.

2

Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development.

Wehbe M, Anantha M, Backstrom I, Leung A, Chen K, Malhotra A, Edwards K, Bally MB. Wehbe M, et al. PLoS One. 2016 Apr 7;11(4):e0153416. doi: 10.1371/journal.pone.0153416. eCollection 2016. PLoS One. 2016. PMID: 27055237 Free PMC article.

3

A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.

Wehbe M, Malhotra A, Anantha M, Roosendaal J, Leung AWY, Plackett D, Edwards K, Gilabert-Oriol R, Bally MB. Wehbe M, et al. Among authors: leung awy. J Control Release. 2017 Apr 28;252:50-61. doi: 10.1016/j.jconrel.2017.03.010. Epub 2017 Mar 10. J Control Release. 2017. PMID: 28286316 Free article.

4

A Perspective - can copper complexes be developed as a novel class of therapeutics?

Wehbe M, Leung AWY, Abrams MJ, Orvig C, Bally MB. Wehbe M, et al. Among authors: leung awy. Dalton Trans. 2017 Aug 22;46(33):10758-10773. doi: 10.1039/c7dt01955f. Dalton Trans. 2017. PMID: 28702645 Review.

5

Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.

Wehbe M, Lo C, Leung AWY, Dragowska WH, Ryan GM, Bally MB. Wehbe M, et al. Among authors: leung awy. Invest New Drugs. 2017 Dec;35(6):682-690. doi: 10.1007/s10637-017-0488-2. Epub 2017 Jul 21. Invest New Drugs. 2017. PMID: 28733701 Free PMC article.

6

Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use.

Chen KTJ, Anantha M, Leung AWY, Kulkarni JA, Militao GGC, Wehbe M, Sutherland B, Cullis PR, Bally MB. Chen KTJ, et al. Among authors: leung awy. Drug Deliv Transl Res. 2020 Feb;10(1):202-215. doi: 10.1007/s13346-019-00674-7. Drug Deliv Transl Res. 2020. PMID: 31482519 Free PMC article.

7

Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia.

Chen KTJ, Militao GGC, Anantha M, Witzigmann D, Leung AWY, Bally MB. Chen KTJ, et al. Among authors: leung awy. J Control Release. 2021 May 10;333:246-257. doi: 10.1016/j.jconrel.2021.03.042. Epub 2021 Mar 30. J Control Release. 2021. PMID: 33798663 Free article.

8

DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation.

Leung AWY, Chen KTJ, Ryan GM, Anantha M, Wretham N, Nosrati Z, Heroux D, Wang L, Chow N, Dai Z, Bally MB. Leung AWY, et al. J Control Release. 2022 May;345:75-90. doi: 10.1016/j.jconrel.2022.03.004. Epub 2022 Mar 5. J Control Release. 2022. PMID: 35259461 Free article.

9

Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.

Leung AW, Kalra J, Santos ND, Bally MB, Anglesio MS. Leung AW, et al. Nanomedicine (Lond). 2014 Mar;9(3):501-22. doi: 10.2217/nnm.13.220. Nanomedicine (Lond). 2014. PMID: 24746193 Review.

10

3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.

Leung AW, Dragowska WH, Ricaurte D, Kwok B, Mathew V, Roosendaal J, Ahluwalia A, Warburton C, Laskin JJ, Stirling PC, Qadir MA, Bally MB. Leung AW, et al. Oncotarget. 2015 Jul 10;6(19):17161-77. doi: 10.18632/oncotarget.3635. Oncotarget. 2015. PMID: 26220590 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34 results

Search Page